Optimal evaluation of monoclonal antibodies (Mab) frequently requires use of quick-frozen cells or tissues not readily available to research and commercial groups. ASA Rule, Inc. plans to develop a rapid service to screen Mabs. This will require the availability of well-organized, quick-frozen panels of normal, benign, and malignant cells (disaggregates or tissues) frozen and maintained at -80(C for rapid screening. When feasible, these cell samples will be covalently linked to glass.Methodologies will be developed (1) for cell meshing, mincing, and dispersal from solid tissues or tumors; (2) for tissue preparation by enzyme treatment with collagenase, trypsin, papain DNA-ase dispase and/or neuraminidase, compared to no treatment of tissue slices; and (3) for separation of cells from debris using density gradients prior to adhesion to activated wells and quick freezing. Methods will be specifically devised and optimized for each organ/tumor system. The immediate aim is to develop the technologies needed to disperse cells prior to freezing. The long-term aim is to develop a service for the assessment of monoclonal antibodies using quick-frozen, viable, cell panels maintained at -80(C.National Cancer Institute (NCI)
